Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Gain Therapeutics, Inc. (GANX)

4.62   -0.055 (-1.18%) 03-17 16:00
Open: 4.8 Pre. Close: 4.675
High: 4.95 Low: 4.62
Volume: 99,547 Market Cap: 55(M)

Technical analysis

as of: 2023-03-17 4:19:28 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 5.78     One year: 6.75
Support: Support1: 4.1    Support2: 3.58
Resistance: Resistance1: 4.94    Resistance2: 5.78
Pivot: 4.07
Moving Average: MA(5): 4.41     MA(20): 4.09
MA(100): 3.54     MA(250): 3.56
MACD: MACD(12,26): 0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 85.5     %D(3): 84.4
RSI: RSI(14): 64.3
52-week: High: 6.69  Low: 2.32
Average Vol(K): 3-Month: 54 (K)  10-Days: 108 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ GANX ] has closed below upper band by 6.7%. Bollinger Bands are 118.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.8 - 4.82 4.82 - 4.83
Low: 4.3 - 4.32 4.32 - 4.33
Close: 4.64 - 4.67 4.67 - 4.7

Company Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Headline News

Fri, 17 Mar 2023
Is Gain Therapeutics Inc (GANX) Stock About to Get Hot Friday? - InvestorsObserver

Wed, 15 Mar 2023
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue ... - Nasdaq

Mon, 13 Mar 2023
Is Gain Therapeutics Inc (GANX) Stock a Bad Value Monday? - InvestorsObserver

Thu, 09 Mar 2023
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual ... - The Bakersfield Californian

Tue, 07 Mar 2023
Should Biotechnology Stock Gain Therapeutics Inc (GANX) Be in Your Portfolio Tuesday? - InvestorsObserver

Mon, 27 Feb 2023
Gain Therapeutics Presents New Preclinical Data from its Gaucher ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 12 (M)
% Held by Insiders 9.18e+006 (%)
% Held by Institutions 24.3 (%)
Shares Short 19 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.64e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -9
Return on Assets (ttm) 719.7
Return on Equity (ttm) -29
Qtrly Rev. Growth 168980
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.03
Qtrly Earnings Growth -1.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -15 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 562.41
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 22400
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.